Few areas of clinical medicine have moved as fast as medical weight management. If you are a physician, nurse practitioner, or physician assistant weighing whether to start prescribing GLP-1 for weight loss, you are stepping into a field that has been reshaped almost every quarter since 2021. What was true about drug availability, compounding, and even which agent produces the most weight loss a year ago may not be true today.
This guide is the hub for clinicians who want a single, current, evidence-grounded reference on GLP-1 receptor agonists for obesity. It walks through how these drugs work at the receptor level, the 2026 treatment landscape, how to select and dose an agent, how to manage side effects and screen for contraindications, and what it takes to build a compliant, sustainable weight-management program. Think of it as the map; the deeper clinical detail on each topic lives in the focused guides linked throughout.
IAPAM has spent more than 20 years training licensed healthcare professionals to add new clinical services safely and confidently. That experience shapes the approach here: practical, honest about uncertainty, and always pointing you back to the primary sources you are accountable to.
Glucagon-like peptide-1 (GLP-1) is an incretin hormone released by the gut after eating. It was first exploited pharmacologically to lower blood glucose in type 2 diabetes, but its effects on body weight turned out to be just as clinically important.
GLP-1 receptor agonists mimic that natural hormone and act through several overlapping pathways. They slow gastric emptying so patients feel full sooner and longer. They act on appetite centers in the hypothalamus and brainstem to reduce hunger and food-seeking behavior. And they enhance glucose-dependent insulin secretion while suppressing glucagon, which is why they also improve glycemic control.
The newer agents add a second or third target. Tirzepatide activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, a dual mechanism associated with greater average weight loss. Investigational triple agonists add glucagon-receptor activity to further increase energy expenditure. Understanding these mechanisms is not academic — it is what explains the differences in efficacy and side-effect profiles you will counsel patients on.
The clinical result across this drug class is consistent: meaningful, sustained weight reduction that, for the leading agents, now rivals what was once achievable only with bariatric surgery. That efficacy is also why patient selection, dosing discipline, and safety monitoring matter so much.
The evidence base is substantial and worth knowing by name, because patients and referring colleagues will ask. Semaglutide’s weight-management data come largely from the STEP trial program, where the 2.4 mg dose produced roughly 15% mean weight loss over 68 weeks (Wilding et al., 2021). Tirzepatide’s efficacy was established in the SURMOUNT program, with the highest dose reaching approximately 21% at 72 weeks (Jastreboff et al., 2022). Beyond weight, the SELECT trial showed that semaglutide reduced major adverse cardiovascular events in patients with overweight or obesity and established cardiovascular disease but without diabetes — the basis for its added cardiovascular indication (Lincoff et al., 2023). This is why these agents are increasingly framed as cardiometabolic therapies, not cosmetic ones.
As of 2026, prescribers have more FDA-approved options for chronic weight management than ever, and the rules around non-approved sources have tightened considerably.
The core approved options a prescriber will reach for include:
| Agent (brand) | Mechanism | Route / frequency | Weight-loss indication |
|---|---|---|---|
| Semaglutide (Wegovy®) | GLP-1 agonist | Subcutaneous, weekly | Chronic weight management; also approved to reduce cardiovascular risk |
| Oral semaglutide (Wegovy® 25 mg) | GLP-1 agonist | Oral, once daily | First GLP-1 pill approved for weight management (December 2025) |
| Tirzepatide (Zepbound®) | Dual GIP/GLP-1 agonist | Subcutaneous, weekly | Chronic weight management; also approved for obstructive sleep apnea in obesity |
| Liraglutide (Saxenda®) | GLP-1 agonist | Subcutaneous, daily | Chronic weight management (older agent, daily dosing) |
Semaglutide is also marketed as Ozempic® and tirzepatide as Mounjaro® for type 2 diabetes. Those diabetes brands are frequently prescribed off-label for weight loss, but for a compliant weight-management program the on-label weight products (Wegovy® and Zepbound®) are the cleaner choice. The December 2025 approval of a 25 mg once-daily oral semaglutide for chronic weight management was a landmark, giving needle-averse patients the first pill in the class with efficacy approaching the injection (American Journal of Managed Care, 2025).
The most closely watched investigational agent is retatrutide, a triple agonist targeting GLP-1, GIP, and the glucagon receptor. In a phase 2 study its highest dose produced approximately 24% mean weight reduction at 48 weeks, and it is now in the phase 3 TRIUMPH program (Jastreboff et al., 2023). Retatrutide is not FDA-approved as of 2026 and should never be presented to patients as an available prescription; discuss it only as emerging trial data on retatrutide dosing. Combination agents such as cagrilintide plus semaglutide are also advancing through late-stage trials.
This is where many clinicians are working from outdated information. During the 2022–2024 shortages, compounded semaglutide and tirzepatide were widely used. Those shortages have since been resolved — the FDA removed tirzepatide from its shortage list in December 2024 and semaglutide in February 2025 — and the compounding grace periods for 503A pharmacies and 503B outsourcing facilities expired in early-to-mid 2025 (Drug Topics, 2025).
In April 2026, the FDA went further, proposing a rule to permanently exclude semaglutide, tirzepatide, and liraglutide from the 503B bulk drug substances list (Pharmacy Times, 2026). Narrow 503A exceptions remain for documented, patient-specific needs such as a genuine excipient allergy or an unavailable dose strength, but routine mass compounding of copies of approved products is no longer permissible — our 2026 regulatory update on compounded semaglutide walks through what still qualifies.
Verify before you prescribeCompounding status in this class has changed several times since 2022 and the April 2026 rule was proposed, not final. Confirm the current FDA position on the day you prescribe, and date-stamp any patient-facing materials you produce so staff can tell at a glance whether a handout is still current.
GLP-1 therapy for weight management is indicated as an adjunct to reduced-calorie diet and increased physical activity. The FDA labeling criteria are a useful floor for candidacy: adults with a body mass index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater accompanied by at least one weight-related comorbidity such as hypertension, type 2 diabetes, dyslipidemia, obstructive sleep apnea, or established cardiovascular disease.
Good candidates are patients who understand this is a long-term therapy, not a short course, and who are prepared to pair medication with nutrition and activity changes. Weight tends to return when the drug is stopped, so willingness to continue treatment — and to be counseled honestly about that reality — is part of appropriate selection.
Some patients are poor candidates or require extra caution: those with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, a history of pancreatitis, severe gastroparesis, active eating disorders, or pregnancy or plans to conceive. Older adults and patients with significant renal or hepatic impairment need individualized assessment. A structured pre-prescribing screen protects both the patient and your practice, and thorough documentation of why a patient was selected is part of defensible prescribing.
A practical intake for a new weight-management patient covers a focused history and, where clinically indicated, baseline labs. Useful elements include the patient’s full weight and dieting history, current medications and supplements (to flag interactions and any agents affected by delayed gastric emptying), personal and family thyroid history, GI and pancreatic history, mental-health and eating-disorder screening, and reproductive plans for patients who could become pregnant. Baseline measurements — weight, BMI, blood pressure, and often a metabolic panel and HbA1c — give you a reference point to demonstrate progress and catch problems early. Selection is not a single yes-or-no gate; it is a documented clinical judgment you can defend if it is ever questioned.
The two dominant injectable agents are semaglutide and tirzepatide, and prescribers now have direct head-to-head evidence to guide the choice.
In the 72-week SURMOUNT-5 trial (751 participants), tirzepatide produced an average 20.2% reduction in body weight versus 13.7% with semaglutide — roughly 50 lbs versus 33 lbs of average loss. Nearly 65% of tirzepatide patients achieved at least 15% weight loss, compared with about 40% on semaglutide (Aronne et al., 2025). On average efficacy, tirzepatide has the edge.
Efficacy is not the only variable, though. Semaglutide has robust cardiovascular outcomes data behind it and a broadly recognized safety record, and the new oral formulation adds a route option that matters for needle-averse patients. Tolerability, insurance coverage, cost, dosing preference (weekly injection versus daily pill versus daily injection for liraglutide), and comorbidities such as sleep apnea all legitimately shape agent selection. The best choice is the one the individual patient can tolerate, afford, and stay on.
Looking ahead, triple agonists like retatrutide may raise the efficacy ceiling further, but until they are approved they should not factor into an actual prescribing decision. Match the agent to the patient in front of you using what is approved and available today.
The single most important principle across this class is start low and go slow. Nearly every tolerability problem traces back to escalating the dose faster than the patient’s gut can adapt. All of these agents use a stepwise titration, typically holding each dose for about four weeks before increasing.
| Agent | Typical titration (verify against current labeling) | Maintenance |
|---|---|---|
| Semaglutide injectable (Wegovy®) | 0.25 → 0.5 → 1.0 → 1.7 → 2.4 mg weekly, ~4 weeks per step | 2.4 mg weekly |
| Tirzepatide (Zepbound®) | 2.5 → 5 → 7.5 → 10 → 12.5 → 15 mg weekly, ~4 weeks per step | 5, 10, or 15 mg weekly |
| Liraglutide (Saxenda®) | 0.6 mg daily, increasing weekly by 0.6 mg | 3.0 mg daily |
| Oral semaglutide (Wegovy®) | Stepwise per labeling to the 25 mg once-daily target | 25 mg once daily |
Titration is a clinical tool, not just a package schedule. If a patient is struggling with side effects at a given dose, it is entirely appropriate to hold at that dose longer, or step back down, before advancing. Many patients achieve satisfactory results below the maximum dose, and the lowest effective dose is a reasonable target. Always confirm the exact schedule against the current prescribing information, since labeling and available dose strengths are periodically updated.
The majority of adverse effects in this class are gastrointestinal: nausea, vomiting, diarrhea, constipation, and abdominal discomfort. In the oral semaglutide trials, for example, roughly three-quarters of patients reported GI symptoms, but they were predominantly mild to moderate and rarely led to permanent discontinuation. Most improve as the body adapts and are minimized by slow titration.
Practical counseling on GI side effects makes a large difference: smaller meals, eating slowly, stopping at the first sign of fullness, staying hydrated, and reducing fatty or very large meals. Setting expectations up front — that some nausea early on is common and usually temporary — prevents avoidable discontinuations.
A few issues deserve specific attention. GLP-1 agents slow gastric emptying, which has raised perioperative aspiration concerns; patients should be counseled to tell any surgeon or anesthesiologist that they are on a GLP-1 before a procedure. Rapid weight loss can contribute to gallbladder disease. And because a meaningful fraction of weight lost can be lean mass, adequate dietary protein and resistance activity are worth building into every treatment plan. Rare but serious events — pancreatitis, ileus — warrant patient education on warning symptoms and a plan for when to seek care.
GLP-1 receptor agonists carry a boxed warning based on rodent studies showing thyroid C-cell tumors. In practice this means they are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), as well as in anyone with known hypersensitivity to the agent (U.S. National Library of Medicine, 2025a, 2025b). Our guide to counseling patients on pancreatitis and thyroid risk covers how to have that conversation without alarming them out of appropriate therapy.
Relative contraindications and cautions include a history of pancreatitis, severe gastroparesis or other significant GI motility disorders, active or prior eating disorders, and pregnancy — these agents should be discontinued when pregnancy is planned or discovered. They are not a substitute for insulin in type 1 diabetes. Renal and hepatic impairment, dehydration risk (particularly with significant vomiting or diarrhea), and interactions with other medications affected by delayed gastric emptying all merit review.
Ongoing monitoring is straightforward but should be deliberate: track weight and blood pressure, reassess glycemic status in diabetic patients, watch for warning signs of pancreatitis and gallbladder disease, and revisit tolerability and adherence at each visit. Document your screening, your counseling, and the patient’s response. Referencing the current FDA prescribing information and guidance from bodies such as the American Association of Nurse Practitioners (AANP) and specialty societies keeps your protocols defensible and current.
The clinical decision is only half of a weight-management program; the financial model is the other half. Insurance coverage for anti-obesity medications remains inconsistent. Some commercial plans cover them with prior authorization and step therapy; others exclude weight-loss drugs entirely. Medicare has historically excluded drugs used solely for weight loss, though coverage pathways have opened where an agent carries an additional approved indication such as cardiovascular risk reduction.
Because of that patchwork, many practices operate cash-pay or membership models for weight management, with transparent pricing for visits and, where appropriate, the medication acquired through the patient’s pharmacy benefit. Prior authorization is often the single biggest operational bottleneck, so building an efficient PA workflow is one of the highest-leverage things a new program can do. Getting the coding for weight-management visits right from day one avoids expensive rework later.
Program economics also improve when weight management sits alongside complementary cash-pay services. Many clinicians who build medical weight-loss offerings also provide aesthetic services, and the same patient relationship supports both. Practices expanding in this direction often pair GLP-1 programs with injectable aesthetics — IAPAM offers Botox® training for nurse practitioners and physician Botox® certification for exactly this kind of service diversification. Whatever the model, code to the actual service delivered, document medical necessity where you bill it, and keep your consent and pricing disclosures clear.
Prescribing GLP-1 medications safely is a genuine clinical skill set: patient selection, titration judgment, side-effect management, safety monitoring, and the operational discipline to run a compliant weight-loss program. Many prescribers were never formally trained in obesity medicine, and the pace of change in this field means even experienced clinicians benefit from structured, current education.
That is the gap IAPAM’s CME-accredited GLP-1 certification training is built to close. Drawing on more than 20 years of experience training healthcare professionals — with programs led by board-certified physician faculty at IAPAM’s Scottsdale, Arizona training clinic and more than 6,300 reviews at a 4.9-star average — the association provides prescribers with the clinical protocols, safety frameworks, and program-building guidance to offer medical weight management confidently.
Formal training is not a legal prerequisite to prescribe, but it is what makes your decisions defensible. If a selection, titration or monitoring choice is ever questioned, the record that helps you is a documented protocol you can point to — and a credential showing where it came from.
For clinicians building a broader cash-pay practice, that GLP-1 foundation pairs naturally with hands-on Botox® training certification, giving one practice two complementary, in-demand service lines. Formal training also strengthens the trust patients place in you and the defensibility of your clinical decisions.
Semaglutide and tirzepatide changed what patients expect from their providers. IAPAM’s GLP-1 certification gives you the protocols, titration schedules, monitoring parameters and side-effect management to run a medically supervised weight management program with confidence.
What the certification covers
For MD/DO, NP, APRN, PA, RN and other licensed providers
GLP-1 Essentials for Weight Loss — self-paced
3 CMEs · 3-5 hours · 24/7 access
Certified Medical Weight Management Provider™ (CWMP)
6 CMEs · 8-10 hours · 24/7 access
Questions? Call 1-866-211-6901
In the head-to-head 72-week SURMOUNT-5 trial, tirzepatide (Zepbound®) produced greater average weight loss than semaglutide (Wegovy®) — about 20.2% versus 13.7% of body weight (Aronne et al., 2025). On average efficacy tirzepatide leads, but the best agent for a given patient depends on tolerability, cost, coverage, route preference, and comorbidities.
In general, yes, where these clinicians have prescriptive authority — but scope of practice varies by state and, for PAs, by supervisory or collaborative arrangements. Verify your own state board’s rules on prescriptive authority and any collaborative-practice requirements before starting a weight-management service.
Largely no for routine use. The FDA declared the semaglutide and tirzepatide shortages resolved in 2025, ending the mass-compounding pathway, and in 2026 proposed permanently excluding these agents from 503B bulk compounding. Narrow 503A exceptions remain for documented patient-specific needs. Always re-verify the current FDA status before relying on any compounded product.
Yes. In December 2025 the FDA approved a 25 mg once-daily oral semaglutide (Wegovy®) for chronic weight management — the first GLP-1 pill approved for weight loss. In its pivotal trial it produced roughly 13.6% mean weight reduction, offering an option for patients who prefer not to inject (American Journal of Managed Care, 2025).
Typically, yes. Obesity is a chronic condition, and studies show substantial weight regain after discontinuation. Patients should be counseled that GLP-1 therapy is generally a long-term treatment, and expectations should be set accordingly at the very first visit.
No. Retatrutide is investigational and not FDA-approved as of 2026, though phase 2 data showed weight loss around 24% at 48 weeks and phase 3 trials are underway (Jastreboff et al., 2023). It should be discussed only as emerging evidence, never offered as an available prescription.
There is no single mandated certification, but formal education in obesity medicine and GLP-1 prescribing significantly improves safety and confidence. Structured programs such as IAPAM’s CME-accredited GLP-1 certification training cover patient selection, titration, side-effect management, and building a compliant program.
Prescribing GLP-1 for weight loss has moved from a niche offering to a mainstream, evidence-backed pillar of medical practice — but it rewards clinicians who stay current. In 2026 that means knowing the approved agents (now including an oral option), understanding the head-to-head efficacy data, respecting the tightened compounding rules, selecting and titrating carefully, and monitoring for the contraindications and side effects that define safe use.
The clinicians who succeed with these medications treat them as one part of a structured, well-run program rather than a quick fix — and they invest in genuine competence. If you are ready to build or strengthen a medical weight-management service, IAPAM’s GLP-1 certification training gives you the clinical protocols and program-building foundation to do it confidently, backed by more than 20 years of training healthcare professionals and over 6,300 five-star reviews.
Explore GLP-1 Certification Training →
Disclaimer: This guide is for informational and educational purposes only and does not constitute medical, legal, or prescribing advice. GLP-1 drug approvals, labeling, and compounding regulations change frequently. Always verify current FDA-approved indications, the manufacturer’s prescribing information, and your state’s scope-of-practice rules before treating any patient.
IAPAM Learning Lab
Patients are already asking about GLP-1s, injectables, PRP, lasers, and aesthetic treatments. Build the knowledge to have better clinical conversations now—on a schedule that works around your practice.
Need hands-on BOTOX® training instead? Explore IAPAM’s Botox training options →
Medical Weight Management Training
Build the clinical, operational, and business foundations to evaluate GLP-1 weight-management services for your practice—without handing your patient relationships to a corporate intermediary.
Explore GLP-1 Certification Training →Want to add Botox® training to your broader practice plan? Explore IAPAM’s Botox training options →
In order to have a successful aesthetic practice, you need to have effective advertising to attract people to your business.
This includes spending those
While Ozempic® has been proven effective in clinical trials, a potential reason for not losing weight on Ozempic® is related to dietary and lifestyle choices.
Failure to refrigerate the Ozempic® within the correct temperature range may result in reduced effectiveness and potential harm to the user.
Learn about the effects of stopping Ozempic® for diabetes & weight loss. Manage withdrawal & maintain health gains.
Request your Quick Start Checklist for Starting or Integrating a New GLP-1 for Weight Loss Guide.
Terms and conditions apply. Offer expires October 31.